Literature DB >> 19482020

Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats.

Valérie F Duvivier1, Laure Delafoy-Plasse, Véronique Delion, Patricia Lechevalier, Jean-Christophe Le Bail, Etienne Guillot, Marie-Pierre Pruniaux, Anne-Marie Galzin.   

Abstract

Recent studies suggested the involvement of the endocannabinoid pathway on insulin secretion in RINm5F cells or rat islets. Animal and clinical studies have reported beneficial effects of the selective cannabinoid 1 receptor antagonist rimonabant on glucose homeostasis. The aim of this study was to investigate the in vivo effects of rimonabant on pancreatic function in Zucker Fatty rats. Zucker Fatty rats were treated with rimonabant (10 mg kg(-1) day(-1)) or vehicle for up to 3 months. Pancreatic function was assessed by oral glucose tolerance test and by static incubation of islets in the presence of different glucose concentrations. Islet morphology was assessed by immuno-histochemistry on pancreatic sections. After 3 months, there was no difference in fasting glycaemia or AUC(glucose) during oral glucose tolerance test between rimonabant- and vehicle-treated animals. However, vehicle-treated rats developed a marked hyperinsulinaemia with time in contrast to rimonabant-treated animals, which maintained at 3 months significantly lower fasting insulin levels (7.76+/-0.67 microg l(-1) vs. 5.59+/-0.59 microg l(-1), P<0.01) and lower AUC(insulin) (1380+/-98 microg l(-1)min vs. 926+/-58 microg l(-1)min, respectively, P<0.001). In static incubation, rimonabant significantly decreased insulin secretion in response to low glucose concentration (3 months: 7.68+/-1.29 vs. 12.25+/-2.01 microg l(-1) 5 islets(-1) 45 min(-1) in rimonabant and vehicle respectively, P<0.01), resulting in a trend to increase stimulation index in the presence of 16.7 mM glucose (10.64+/-0.92 vs. 8.52+/-1.70 respectively). Morphological analysis at 3 months showed that rimonabant reduced islet-cell surface (-60%) and the percentage of disorganized islets (-54%).In conclusion, our data suggest that rimonabant has a protective role against the development of hyperinsulinaemia, beta-cell dysfunction and islet modification in Zucker Fatty rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482020     DOI: 10.1016/j.ejphar.2009.05.024

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.

Authors:  Christopher J Lynch; Qing Zhou; Show-Ling Shyng; David J Heal; Sharon C Cheetham; Keith Dickinson; Peter Gregory; Michael Firnges; Ulrich Nordheim; Stephanie Goshorn; Dania Reiche; Lechoslaw Turski; Jochen Antel
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-12-13       Impact factor: 4.310

2.  Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice.

Authors:  Isabel González-Mariscal; Susan M Krzysik-Walker; Wook Kim; Michael Rouse; Josephine M Egan
Journal:  Mol Cell Endocrinol       Date:  2015-12-25       Impact factor: 4.102

Review 3.  The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.

Authors:  Alain Veilleux; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

4.  Effects of Chronic Antagonism of Endocannabinoid-1 Receptors on Glucose Tolerance and Insulin Action in Skeletal Muscles of Lean and Obese Zucker Rats.

Authors:  Katherine A Lindborg; Stephan Jacob; Erik J Henriksen
Journal:  Cardiorenal Med       Date:  2011-01-17       Impact factor: 2.041

5.  Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.

Authors:  Dai Lu; Rachel Dopart; Debra A Kendall
Journal:  Cell Stress Chaperones       Date:  2016-01       Impact factor: 3.667

6.  CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.

Authors:  Tony Jourdan; Louiza Djaouti; Laurent Demizieux; Joseph Gresti; Bruno Vergès; Pascal Degrace
Journal:  Diabetes       Date:  2010-01-28       Impact factor: 9.461

Review 7.  Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes.

Authors:  T Jourdan; G Godlewski; G Kunos
Journal:  Diabetes Obes Metab       Date:  2016-03-31       Impact factor: 6.577

8.  Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.

Authors:  Sang-Man Jin; Bae Jun Oh; Suel Lee; Jung Mook Choi; Soo Jin Yang; Sung Woo Park; Kwang-Won Kim; Jae Hyeon Kim; Cheol-Young Park
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

9.  Prolonged activation of human islet cannabinoid receptors in vitro induces adaptation but not dysfunction.

Authors:  Alonso Vilches-Flores; Zara Franklin; Astrid C Hauge-Evans; Bo Liu; Guo C Huang; Pratik Choudhary; Peter M Jones; Shanta J Persaud
Journal:  BBA Clin       Date:  2016-03-30

10.  The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice.

Authors:  Francisco J Bermudez-Silva; Silvana Y Romero-Zerbo; Magalie Haissaguerre; Inmaculada Ruz-Maldonado; Said Lhamyani; Rajaa El Bekay; Antoine Tabarin; Giovanni Marsicano; Daniela Cota
Journal:  Dis Model Mech       Date:  2015-11-12       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.